Novartis presented the data of Kymriah in patients suffering from DLBCL and ALL. Janssen presented the data of JNJ-4528 in patients suffering from multiple myeloma. Kite has shown the data of Yescarta in relapsed or refractory large B-cell lymphoma. BMS presented results of bb21217 in relapsed/refractory multiple myeloma.
Novartis presented the data of Kymriah (tisagenlecleucel) approved for diffuse large B cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (ALL). Kymriah efficacy in patients suffering from DLBCL was the 24-month analysis of JULIET in adults. In the 24-month study, 52% is the overall response rate (ORR) and 38% complete response (CR). In patients suffering from ALL, the real-world setting had more favorable outcomes than ELIANA pivotal trial. CR was 85% compared to 82% in the ELIANA trial.
Janssen Pharmaceuticals presented the Phase 1b/2 CARTITUDE-1 study of JNJ-4528. JNJ-4528 is an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) indicated for the treatment of relapsed or refractory multiple myeloma. Twenty-nine patients included in the trial, 69% achieved an overall response rate (ORR), 66% achieved stringent CR. 86% achieved a very good partial response (VGPR) or better. Cytokine release syndrome, neutropenia, anemia and thrombocytopenia were the common adverse events reported in the trial.
Kite and CIBMTR presented the real-world use results of Yescarta (axicabtagene ciloleucel) in patients suffering from relapsed or refractory large B-cell lymphoma. The company post-marketing study showed comparable safety and efficacy to ZUMA-1 pivotal trial. The study included 533 patients. 84% of patients achieved an overall response rate (ORR), and 66% of patients achieved a complete response.
Bluebird bio, Inc and Bristol-Myers Squibb presented the data of bb21217 in the patients suffering from relapsed/refractory multiple myeloma. bb21217 is a BCMA-targeted chimeric antigen receptor (CAR) T cell therapy. “Early data from the CRB-402 study in heavily pre-treated patients (median of six prior lines) with relapsed/refractory multiple myeloma demonstrate the potential for durable responses following bb21217 CAR T cell treatment, with a median duration of response of 11.1 months at the 150 x 106 CAR+ T cell dose level,” said David Davidson, M.D., chief medical officer, bluebird bio.